Robotic and traditional mitral valve repair surgeries are mostly associated with similar outcomes when treating elderly patients. In some ways, however, robotic procedures may be preferred.
Consulting fees and other vendor payments do not appear to be directly influencing U.S. physicians to implant more Watchman devices. Researcher Alexander Kolomaya, MD, discussed his team's findings on this topic.
The mobile power units of certain HeartMate 3 and HeartMate II LVADs have been experiencing “sudden, unexpected performance issues” such as turning on, off or even restarting with no warning. These issues can potentially be fatal, according to an alert shared by the FDA.
Same-day discharge won't always be a great fit after cardiac ablation, of course, but it has been associated with considerable patient satisfaction as well as improved efficiency and substantial cost savings. The Heart Rhythm Society and American College of Cardiology have shared a new scientific statement on the subject.
Field Medical, founded in 2022 by Steven Mickelsen, MD, is set to make a significant splash at the Heart Rhythm Society's annual meeting in San Diego. The company also just raised $40 million in financing.
Michael Reardon, MD, detailed five-year data out of ACC.25 that found Medtronic's Evolut TAVR platform performs as well as SAVR—and even better in some ways.
Two of the world's leading medtech companies have been collaborating to improve patient access to CGM technology. It now looks like Medtronic and Abbott could be close to gaining FDA clearance and moving forward to the next phase of their partnership.
The devices are being recalled and discontinued after the FDA shared a series of concerns. This is a Class I recall, meaning using this system could result in serious injuries or death.
The late-breaking five-year results of the Evolut Low-Risk Trial presented at the American College of Cardiology (ACC) 2025 meeting in late March, showed positive results for the Evolut transcatheter aortic valve replacement (TAVR) system vs. surgical aortic valve replacement (SAVR).
Radiology practices are already operating on razor thin margins, with price increases prompting calls for congressional action to prevent further damage.
